Top 10 Reasons to Buy IVST

1. 1st stage breakout just completed, IVST is ready for another move
after holding $0.40 support. Full size chart: https://tinyurl.com/y9lbw7xr

2. Grown from $0 revenue to $34M revenue this year

3. LOI on pending acquisition to add $12M in revenue

4. 20% ownership in Stem Vax. StemVax brain tumor vaccine has been
granted patent approval after a nine year filing process

5. First half 2018 revenue growth 55.8%

6. No convertible debts, no warrants or options outstanding

7. Current assets of $877,861; Cash balance of $561,062

8. Winslow Asset Management, the first institutional investor in
Innovest Global, filed showing that they remain a long shareholder

9. Leadership under Dan Martin has been tremendous. Investor Video:
https://www.youtube.com/watch?v=_hgl5vGvMU0#action=share

10. Shares Outstanding Shares 109M 9/14/18. Float Shares 11.8M 8/16/18
(no changes in over 2 years)

https://www.innovestglobal.com/

Leave a Reply

Your email address will not be published.Required fields are marked *